Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Scott Gottlieb, the former commissioner of the Food and Drug Administration (FDA) during President-elect Trump’s first term, ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...